CRDFCardiff Oncology, Inc.

$133M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51,687-41.5% YoY

Gross Profit

-$3M-5353.6% margin

Operating Income

-$4M-8140.3% margin

Net Income

-$4M-8012.7% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-62.5%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$266,325

Balance Sheet

Total Assets

$12M

Total Liabilities

$5M

Stockholders' Equity

$7M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51,687	$88,361	-41.5%
Gross Profit	-$3M	$61,684	-4586.0%
Operating Income	-$4M	-$4M	-9.1%
Net Income	-$4M	-$4M	-9.9%

Revenue Segments

Royalty

$51,687100%

CRDF Q3 2019 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena